BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25839711)

  • 1. Chemokines in the melanoma metastasis biomarkers portrait.
    Neagu M; Constantin C; Longo C
    J Immunoassay Immunochem; 2015; 36(6):559-66. PubMed ID: 25839711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma.
    McConnell AT; Ellis R; Pathy B; Plummer R; Lovat PE; O'Boyle G
    Br J Dermatol; 2016 Dec; 175(6):1210-1220. PubMed ID: 27167239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of chemokine receptor CXCR4 mRNA in primary cutaneous melanoma with established histopathologic prognosticators and the BRAF status.
    Mitchell B; Leone D; Feller JK; Bondzie P; Yang S; Park HY; Mahalingam M
    Melanoma Res; 2014 Dec; 24(6):621-5. PubMed ID: 25211166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone receptor-independent CXCL10 production is associated with the regulation of cellular factors linked to breast cancer progression and metastasis.
    Ejaeidi AA; Craft BS; Puneky LV; Lewis RE; Cruse JM
    Exp Mol Pathol; 2015 Aug; 99(1):163-72. PubMed ID: 26079660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CXCR4/CXCL12 axis in cutaneous malignancies with an emphasis on melanoma.
    Mitchell B; Mahalingam M
    Histol Histopathol; 2014 Dec; 29(12):1539-46. PubMed ID: 24879309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein expression of the chemokine receptor CXCR4 and its ligand CXCL12 in primary cutaneous melanoma--biomarkers of potential utility?
    Mitchell B; Leone D; Feller K; Menon S; Bondzie P; Yang S; Park HY; Mahalingam M
    Hum Pathol; 2014 Oct; 45(10):2094-100. PubMed ID: 25130395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular Metastasis of BRAF+ Cutaneous Malignant Melanoma.
    Gonzalez A; Miles JF; Khurshid GS
    Ophthalmol Retina; 2018 Jan; 2(1):71. PubMed ID: 31047306
    [No Abstract]   [Full Text] [Related]  

  • 8. Chemokine receptor CCR7 expression predicts poor outcome in uveal melanoma and relates to liver metastasis whereas expression of CXCR4 is not of clinical relevance.
    van den Bosch T; Koopmans AE; Vaarwater J; van den Berg M; de Klein A; Verdijk RM
    Invest Ophthalmol Vis Sci; 2013 Nov; 54(12):7354-61. PubMed ID: 24052640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The metastatic microenvironment: Brain-derived soluble factors alter the malignant phenotype of cutaneous and brain-metastasizing melanoma cells.
    Klein A; Sagi-Assif O; Izraely S; Meshel T; Pasmanik-Chor M; Nahmias C; Couraud PO; Erez N; Hoon DS; Witz IP
    Int J Cancer; 2012 Dec; 131(11):2509-18. PubMed ID: 22447293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients.
    Hofman V; Ilie M; Long-Mira E; Giacchero D; Butori C; Dadone B; Selva E; Tanga V; Passeron T; Poissonnet G; Emile JF; Lacour JP; Bahadoran P; Hofman P
    J Invest Dermatol; 2013 May; 133(5):1378-81. PubMed ID: 23303445
    [No Abstract]   [Full Text] [Related]  

  • 11. A Case of Giant Primary Dermal Melanoma with BRAF V600E Mutation.
    Imamura T; Nakamura Y; Teramoto Y; Sato S; Asami Y; Arai E; Yamamoto A
    Acta Derm Venereol; 2016 Aug; 96(6):840-1. PubMed ID: 26984828
    [No Abstract]   [Full Text] [Related]  

  • 12. CXCR4, CXCL12 and the relative CXCL12-CXCR4 expression as prognostic factors in colon cancer.
    Stanisavljević L; Aßmus J; Storli KE; Leh SM; Dahl O; Myklebust MP
    Tumour Biol; 2016 Jun; 37(6):7441-52. PubMed ID: 26678887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Map3k1 Loss Cooperates with Braf
    Trucco LD; Mundra PA; García-Martínez P; Hogan K; Baenke F; Dhomen N; Pavet V; Marais R
    J Invest Dermatol; 2021 Jan; 141(1):221-225.e6. PubMed ID: 32450073
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
    Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
    Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locally generated VGVAPG and VAPG elastin-derived peptides amplify melanoma invasion via the galectin-3 receptor.
    Pocza P; Süli-Vargha H; Darvas Z; Falus A
    Int J Cancer; 2008 May; 122(9):1972-80. PubMed ID: 18076073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stage-specific prognostic biomarkers in melanoma.
    Cheng Y; Lu J; Chen G; Ardekani GS; Rotte A; Martinka M; Xu X; McElwee KJ; Zhang G; Zhou Y
    Oncotarget; 2015 Feb; 6(6):4180-9. PubMed ID: 25784655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCL27-CCR10 and CXCL12-CXCR4 chemokine ligand-receptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma.
    Monteagudo C; Ramos D; Pellín-Carcelén A; Gil R; Callaghan RC; Martín JM; Alonso V; Murgui A; Navarro L; Calabuig S; López-Guerrero JA; Jordá E; Pellín A
    Clin Exp Metastasis; 2012 Aug; 29(6):625-37. PubMed ID: 22526457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and
    García-Silva S; Benito-Martín A; Sánchez-Redondo S; Hernández-Barranco A; Ximénez-Embún P; Nogués L; Mazariegos MS; Brinkmann K; Amor López A; Meyer L; Rodríguez C; García-Martín C; Boskovic J; Letón R; Montero C; Robledo M; Santambrogio L; Sue Brady M; Szumera-Ciećkiewicz A; Kalinowska I; Skog J; Noerholm M; Muñoz J; Ortiz-Romero PL; Ruano Y; Rodríguez-Peralto JL; Rutkowski P; Peinado H
    J Exp Med; 2019 May; 216(5):1061-1070. PubMed ID: 30975894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells.
    Murakami T; Maki W; Cardones AR; Fang H; Tun Kyi A; Nestle FO; Hwang ST
    Cancer Res; 2002 Dec; 62(24):7328-34. PubMed ID: 12499276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF V600E mutation-specific antibody: A review.
    Ritterhouse LL; Barletta JA
    Semin Diagn Pathol; 2015 Sep; 32(5):400-8. PubMed ID: 25744437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.